Difluoroescaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Difluoroescaline (DFE), also known as 4-(2,2-difluoroethoxy)-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3] It is a difluorinated derivative of escaline.[1][2][3]
- None
| |
| Clinical data | |
|---|---|
| Other names | DFE; 2,2-DFE; F2EM; 4-(2,2-Difluoroethoxy)-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-(2,2-difluoroethoxy)phenethylamine |
| Routes of administration | Oral[1][2][3] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 6–12 hours[1][2][3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C12H17F2NO3 |
| Molar mass | 261.269 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Its dose range is 40 to 80 mg and its duration is 6 to 12 hours.[1][2][3] The drug's effects include color enhancement, some closed-eye and open-eye visuals, emotional changes, and some physical discomfort.[1]
It acts as a low-potency partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets.[3][2]
The chemical synthesis of difluoroescaline has been described.[4]
Difluoroescaline was first described in the scientific literature by Daniel Trachsel in 2002.[1][2][3][4] Its pharmacology was studied in more detail in 2021.[3] It is not a controlled substance in Canada as of 2025.[5]